Lloyd Segal

Biovail Corp. develops and manufactures pharmaceutical products. The company provides different types of products which include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. Its products are used for cardiovascular disease, central nervous system disorders, pain management and other niche areas. It was founded on March 29, 1994 and is headquartered in Mississauga, Canada.

Caprion Pharmaceuticals, Inc. discovered and developed pharmaceutical products. It offered a proprietary therapeutic pipeline in oncology and infectious diseases. Caprion Pharmaceuticals proteomics discovery technologies used to enable the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that can significantly enhance clinical development productivity and decision making. The company was founded in 1998 and was headquartered in Montreal, Canada.

Therapure Biopharma, Inc. engages in the business of contract development and manufacturing. It operates through the following divisions: Therapure Biomanufacturing, Therapure Innovations, and Evolve Biologics. The Therapure Biomanufacturing division focuses on contract development and manufacturing of complex biologics. The Therapure Innovations division includes in-house proprietary-drug development. The Evolve Biologics division develops a portfolio of plasma-derived pharmaceutical products. The company was founded on June 22, 2007 and is headquartered in Mississauga, Canada.

Part of Nen Tm Life Science Products, Inc., Advanced Bioconcept Ltd. is a Canadian company that makes proprietary, fluorescent labeled peptides. The company is based in Montréal, Canada. The company was founded by Clarissa Desjardins. Advanced Bioconcept was acquired by Nen Tm Life Science Products, Inc. on September 25, 1998.

Thallion Pharmaceuticals, Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its products are Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections and TLN-4601, a proprietary first in class small molecule with potential efficacy in multiple oncology indications. The company was founded in January 1998 and is headquartered in Dorval, Canada.